Category Archives: Insulin Delivery

Arrowhead CY Q3 ’24 (FY Q4 ’24) Earnings; Embecta Discontinues Patch Pump; New Medicare and Medicaid Obesity Proposal; EOFlow Wins Legal Battle in the EU

This content is for Read Less members only.
Register

Already a member? Log in here

Lilly and Laekna Obesity Partnership; Viking Ph2b MASH Data; Medtronic InPen App FDA Clearance; Omnipod 5 and FreeStyle Libre 2 Plus Integration; Flagship and Ampersand Obesity Partnership; NewAmsterdam Ph3 TANDEM CV Data

A series of cardiometabolic-related news items have been observed from Lilly, Viking, Medtronic, Insulet, Pfizer, and NewAmsterdam Pharma. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Insulet, Senseonics, Akero, Skye, MannKind, and Xeris Q3 ’24 Earnings

A series of cardiometabolic-related news items have been observed from Insulet, Senseonics, Akero Therapeutics, Skye Bioscience, MannKind, and Xeris. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

QW Icodec CRL Information; Beta Bionics Launches Libre 3+ Integration; O5 iOS App US Launch; Zealand Obesity Trial

A series of cardiometabolic-related news items have been observed from FDA/Novo Nordisk, Beta Bionics, Insulet, and Zealand Pharma. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Viking Q3 ’24 Earnings; Luna Initiates AID Trial; Fable Obesity Startup; Mounjaro Denmark Launch

A series of cardiometabolic-related news items have been observed from Viking Therapeutics, Fable Therapeutics, Luna Diabetes, and Lilly. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Abbott Q3 ’24 Earnings; Neurogastrx’s NG101 Reduces GLP-1RA-Related AEs; Kaleido Insulin Pump Receives CE Mark; Alnylam Submits Vutrisiran to EMA

A series of cardiometabolic-related news items have been observed from Abbott, Neurogastrx, ViCentra, and Alnylam Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

BI Receives BTD for Survodutide and Initiates 2 Ph3 MASH Trials; Roche Ph2 CT-388 Trial in Obesity+T2DM; Drug Compounder Group Sues FDA; WeightWatchers to Offer Compounded Semaglutide; Novo Invests $158M in Insulin Plant

A series of cardiometabolic-related news items have been observed from Boehringer Ingelheim, Roche, the Outsourcing Facilities Association, WeightWatchers, and Novo Nordisk. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Elevai Files Patents For Obesity Lean Mass Preservation; Medtronic Pump Recall

Two cardiometabolic-related news items have been observed: Elevai Biosciences announced it filed two patent applications for EL-22 (oral myostatin engineered probiotic) as a monotherapy or combination with GLP-1RAs (view press release); and Medtronic announced a voluntary recall of its MiniMed 600/700 series insulin pumps due to shortened battery life issues (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Roche Pharma Day; Rezdiffra QoL Publication; Pemvidutide Trial Enrollment Updates; NeuroBo Ph1 Obesity Readout; MannKind Afrezza Data

A series of cardiometabolic-related news items have been observed from Roche, Madrigal, Altimmune, NeuroBo, and MannKind. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Novo CB1 Ph2a Obesity Topline Results; Two Ph3 Tirzepatide Combo Psoriatic Studies Observed; Aligos Ph2a MASH Topline Results; AZ Initiates Ph2 LA Amylin Obesity Study; FTC Sues PBMs; Synjardy Receives Pediatric CHMP Positive Opinion

A series of cardiometabolic-related news items have been observed from Novo Nordisk, Lilly, Aligos Therapeutics, AstraZeneca, FTC, and CHMP. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here